Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIREL SANCHEZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1740401322
CMS profile
215811
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,667.72

91 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,990.05 88
Travel and Lodging $677.67 3

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIREL SANCHEZ

NPI 1740401322 · CMS profile ID 215811

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740401322?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIREL SANCHEZ, NPI 1740401322, CMS profile ID 215811. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740401322?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MIREL SANCHEZ, NPI 1740401322, CMS profile ID 215811. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740401322?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MIREL SANCHEZ, NPI 1740401322, CMS profile ID 215811, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1740401322?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

91 matching records · $2,667.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 91 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–91 of 91.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $22.2007/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885961309 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.0006/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959392105 CMS
Lilly USA, LLC $17.1306/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918206333 CMS
Janssen Pharmaceuticals, Inc $20.5006/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885961273 CMS
Biohaven Pharmaceutical Holding Company Ltd. $20.7406/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923722293 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.7805/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959822051 CMS
Janssen Pharmaceuticals, Inc $18.5305/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885961279 CMS
Lilly USA, LLC $12.4605/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918206339 CMS
Radius Health, Inc. $14.5505/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954951229 CMS
Janssen Pharmaceuticals, Inc $25.1105/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885961303 CMS
AstraZeneca Pharmaceuticals LP $19.8305/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915541994 CMS
Novo Nordisk Inc $22.9605/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898711259 CMS
Corcept Therapeutics $11.8305/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948774201 CMS
Bayer HealthCare Pharmaceuticals Inc. $23.5204/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930129983 CMS
AstraZeneca Pharmaceuticals LP $15.4004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915401073 CMS
Biohaven Pharmaceutical Holding Company Ltd. $19.5204/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923722291 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.8504/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959804231 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.3204/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887591337 CMS
AstraZeneca Pharmaceuticals LP $17.7204/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915446343 CMS
Janssen Pharmaceuticals, Inc $18.6804/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885961297 CMS
Bayer HealthCare Pharmaceuticals Inc. $27.1004/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930142595 CMS
Lilly USA, LLC $16.3703/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918242629 CMS
Corcept Therapeutics $122.2503/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948774197 CMS
AstraZeneca Pharmaceuticals LP $24.1503/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914743017 CMS
Novo Nordisk Inc $21.9003/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899384283 CMS
AstraZeneca Pharmaceuticals LP $18.4803/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914622307 CMS
Lilly USA, LLC $13.8503/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918207295 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.6603/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959984255 CMS
Novo Nordisk Inc $18.7803/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899193901 CMS
Janssen Pharmaceuticals, Inc $20.4903/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885961267 CMS
AstraZeneca Pharmaceuticals LP $17.7202/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915866897 CMS
Lilly USA, LLC $12.0702/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918230379 CMS
Amarin Pharma Inc. $21.6702/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913959509 CMS
Corcept Therapeutics $7.9402/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948774105 CMS
Novo Nordisk Inc $20.6202/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899656601 CMS
Janssen Pharmaceuticals, Inc $19.4801/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885961321 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.6601/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959812195 CMS
AstraZeneca Pharmaceuticals LP $20.4601/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914633493 CMS
Bayer HealthCare Pharmaceuticals Inc. $22.9801/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930300681 CMS
Lilly USA, LLC $13.1301/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918230381 CMS
Janssen Pharmaceuticals, Inc $18.1801/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885961315 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $788.33 42
PY2020 $2,996.64 125
PY2021 $1,742.09 100
PY2022 $2,667.72 91
PY2023 $552.68 22
PY2024 $963.06 41
PY2025 $2,953.10 56

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $770.59 6
PY2025 Principal investigator $407,541.55 54
PY2024 Recipient $946.99 7
PY2024 Principal investigator $290,989.51 31
PY2023 Recipient $71,515.00 3
PY2023 Principal investigator $402,271.35 9
PY2022 Principal investigator $331,538.65 24
PY2021 Recipient $35.51 1
PY2021 Principal investigator $171,842.44 43
PY2020 Principal investigator $247,564.65 69
PY2019 Recipient $80,244.31 9
PY2019 Principal investigator $467,584.86 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $14,160.00 12/22/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133276
Principal investigator 1 SANOFI US SERVICES INC. $16,407.60 11/17/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133273
Principal investigator 1 Janssen Research & Development, LLC $258.00 10/27/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175194182
Principal investigator 1 Janssen Research & Development, LLC $258.00 10/27/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196096
Principal investigator 1 Janssen Research & Development, LLC $258.00 10/27/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196251
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 10/27/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196803
Principal investigator 1 Janssen Research & Development, LLC $1,903.00 10/27/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196990
Principal investigator 1 Janssen Research & Development, LLC $1,903.00 10/27/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175197199
Principal investigator 1 SANOFI US SERVICES INC. $1,050.00 10/14/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133255
Principal investigator 1 SANOFI US SERVICES INC. $14,114.20 10/14/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133261
Principal investigator 1 Madrigal Pharmaceuticals $2,587.34 10/03/2025 Non-covered Recipient Entity
SANCHEZ CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251129
Principal investigator 1 SANOFI US SERVICES INC. $27,051.20 09/15/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133252
Principal investigator 1 SANOFI US SERVICES INC. $5,530.00 09/03/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133249
Recipient ABBVIE INC. $60.00 08/22/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202401110
Recipient ABBVIE INC. $25.00 08/22/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202401113
Recipient ABBVIE INC. $70.00 08/22/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202401117
Recipient ABBVIE INC. $261.53 08/22/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202401122
Recipient ABBVIE INC. $150.00 08/21/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202401103
Recipient ABBVIE INC. $204.06 08/21/2025 Covered Recipient Physician A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202401106
Principal investigator 1 SANOFI US SERVICES INC. $9,652.00 08/11/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133235
Principal investigator 1 SANOFI US SERVICES INC. $19,091.00 08/11/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133239
Principal investigator 1 Janssen Research & Development, LLC $2,737.00 07/28/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175194254
Principal investigator 1 Janssen Research & Development, LLC $258.00 07/28/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175195407
Principal investigator 1 Janssen Research & Development, LLC $1,903.00 07/28/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196552
Principal investigator 1 Janssen Research & Development, LLC $2,243.00 07/28/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196570
Principal investigator 1 Janssen Research & Development, LLC $258.00 07/28/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196961
Principal investigator 1 Janssen Research & Development, LLC $258.00 07/28/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175197275
Principal investigator 1 SANOFI US SERVICES INC. $13,136.20 07/14/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133231
Principal investigator 1 Madrigal Pharmaceuticals $2,203.70 07/10/2025 Non-covered Recipient Entity
SANCHEZ CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246913
Principal investigator 1 SANOFI US SERVICES INC. $8,501.00 07/02/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133223
Principal investigator 1 SANOFI US SERVICES INC. $11,293.00 06/16/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133211
Principal investigator 1 SANOFI US SERVICES INC. $20,999.00 06/09/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133196
Principal investigator 1 SANOFI US SERVICES INC. $2,970.00 06/09/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133200
Principal investigator 1 SANOFI US SERVICES INC. $15,849.60 05/19/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133219
Principal investigator 1 Madrigal Pharmaceuticals $2,587.34 05/15/2025 Non-covered Recipient Entity
SANCHEZ CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243675
Principal investigator 1 Janssen Research & Development, LLC $258.00 05/12/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175194188
Principal investigator 1 Janssen Research & Development, LLC $258.00 05/12/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175195323
Principal investigator 1 Janssen Research & Development, LLC $1,903.00 05/12/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175195440
Principal investigator 1 Janssen Research & Development, LLC $258.00 05/12/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196008
Principal investigator 1 Janssen Research & Development, LLC $2,243.00 05/12/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196237
Principal investigator 1 Janssen Research & Development, LLC $1,903.00 05/12/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196908
Principal investigator 1 SANOFI US SERVICES INC. $15,929.00 05/05/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133191
Principal investigator 1 SANOFI US SERVICES INC. $16,617.80 04/07/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133188
Principal investigator 1 ABBVIE INC. $13,756.40 04/03/2025 Non-covered Recipient Entity
SANCHEZ CLINICAL RESEARCH INC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202468938
Principal investigator 1 SANOFI US SERVICES INC. $9,891.00 04/02/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133164
Principal investigator 1 SANOFI US SERVICES INC. $8,740.00 03/24/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133156
Principal investigator 1 SANOFI US SERVICES INC. $5,104.40 03/17/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133176
Principal investigator 1 Janssen Research & Development, LLC $258.00 02/26/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175194114
Principal investigator 1 Janssen Research & Development, LLC $2,243.00 02/26/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175194543
Principal investigator 1 Janssen Research & Development, LLC $258.00 02/26/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175194680
Principal investigator 1 Janssen Research & Development, LLC $2,737.00 02/26/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175195185
Principal investigator 1 Janssen Research & Development, LLC $1,903.00 02/26/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175195268
Principal investigator 1 Janssen Research & Development, LLC $469.00 02/26/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175195569
Principal investigator 1 Janssen Research & Development, LLC $258.00 02/26/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196052
Principal investigator 1 Janssen Research & Development, LLC $258.00 02/26/2025 Non-covered Recipient Entity
Sanchez Clnc Rsrch Inc.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175196644
Principal investigator 1 SANOFI US SERVICES INC. $77,229.20 02/24/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133180
Principal investigator 1 Madrigal Pharmaceuticals $11,402.11 02/06/2025 Non-covered Recipient Entity
SANCHEZ CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239354
Principal investigator 1 SANOFI US SERVICES INC. $11,428.00 02/04/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133172
Principal investigator 1 SANOFI US SERVICES INC. $15,690.00 01/21/2025 Non-covered Recipient Entity
Sanchez Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133148
Principal investigator 1 ABBVIE INC. $4,896.46 01/02/2025 Non-covered Recipient Entity
SANCHEZ CLINICAL RESEARCH INC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202435572